Key facts
- This page summarizes Heath Lukatch's Form 4 filing for Vaxcyte, Inc. (PCVX).
- 4 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 12 Jan 2023, 15:33.
Heath Lukatch - 10 Jan 2023 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)
- Role
- Director
- Signature
- Heath Lukatch, by /s/ Ron A. Metzger, Attorney-in-Fact
- Issuer symbol
- PCVX
- Transactions as of
- 10 Jan 2023
- Net transactions value
- -$9,486
- Form type
- 4
- Filing time
- 12 Jan 2023, 15:33:18 UTC
- Previous filing
- 14 Dec 2022
- Next filing
- 08 Jun 2023
- SEC
- View on sec.gov
Key filing fact
Heath Lukatch filed Form 4 for Vaxcyte, Inc. (PCVX) on 12 Jan 2023.
Change
- Previous filing in this sequence was filed on 14 Dec 2022.
- Current net transaction value: -$9,486.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
PCVX
transaction
Common Stock
Options Exercise
- Transaction value
- $5,040
- Shares
- +315
- Change %
- +10%
- Price
- $16.00
- Shares after
- 3,440
- Date
- 10 Jan 2023
- Ownership
- Direct
PCVX
transaction
Common Stock
Sale
- Transaction value
- $10,728
- Shares
- -233
- Change %
- -6.8%
- Price
- $46.04
- Shares after
- 3,207
- Date
- 10 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F2
PCVX
transaction
Common Stock
Sale
- Transaction value
- $3,799
- Shares
- -82
- Change %
- -2.6%
- Price
- $46.33
- Shares after
- 3,125
- Date
- 10 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F3
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
PCVX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -315
- Change %
- -1.1%
- Price
- $0.000000
- Shares after
- 28,000
- Date
- 10 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 315
- Exercise price
- $16.00
- Footnotes
- F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| F2 | The price reported is a weighted-average price. The shares were sold at prices ranging from $45.27 to $46.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| F3 | The price reported is a weighted-average price. The shares were sold at prices ranging from $46.29 to $46.385. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| F4 | 1/3 of the shares subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter. |